Why Is Vir Biotechnology Stock Falling Friday?

November 13, 2026 Akanksha Bakshi

Summary

Shares of Vir Biotechnology dropped in premarket trading on Friday. The decline followed the biopharmaceutical company's announcement of a major public stock offering. Investors are reacting to concerns that the new equity sale will dilute the value of existing shares.

Vir Biotechnology, Inc. (NASDAQ:VIR) stock fell in Friday’s premarket trading after the clinical-stage biopharmaceutical company priced a $150 million public stock offering at $10 per share, raising concerns about shareholder dilution.$150 Million Equity OfferingVir Biotechnology priced 15 million common shares at $10 each, expecting gross proceeds of $150 million before underwriting discounts, commissions, and expenses.The company granted underwriters a 30-day…

Source: Read the full story at Top Stories Feed

Follow Tech & Money Press for daily watchlists and market news

X Facebook Instagram TikTok

Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.